Recursion Pharmaceuticals, Inc. (RXRX)

8,84 +0,05 (+0,57%) Alla chiusura: 04:00PM EDT

Recursion Pharmaceuticals, Inc.

41 South Rio Grande Street
Salt Lake City, UT 84101
United States
385 269 0203
https://www.recursion.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 500

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Christopher C. Gibson Ph.D.	Co-Founder, CEO & Director	806,72k	2,18M	1983
Ms. Tina Marriott Larson	COO & President	702,24k	397,61k	1975
Dr. Blake C. Borgeson Ph.D.	Co-Founder & Director	40k	N/D	1982
Dr. Michael Secora Ph.D.	Chief Financial Officer	629,78k	3,62M	1983
Dr. David J. Mauro M.D., Ph.D.	Chief Medical Officer	674,74k	N/D	1965
Kevin Leggat	Vice President of Finance & Accounting	N/D	N/D	N/D
Mr. Benjamin Mabey M.S.	Chief Technology Officer	N/D	N/D	1983
Mr. Jared Allenbach	Senior Director of Investor Relations	N/D	N/D	N/D
Mr. Nathan Hatfield	Chief Legal Officer & General Counsel	N/D	N/D	N/D
Mr. Ryan Kelly	Chief Communications Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Governance aziendale

L'ISS Governance QualityScore di Recursion Pharmaceuticals, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 6; diritti degli azionisti: 10; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.